SCHEMBL12604690

SCHEMBL12604690

BCc1ccc(C(C)(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
LMNA P02545 1/20 0.46
TYR P14679 1/20 0.46
KCNH2 Q12809 1/20 0.45
TP53 P04637 1/20 0.45
BCHE P06276 4/20 0.45
ACHE P22303 4/20 0.45
APP P05067 1/20 0.42
SIGMAR1 Q99720 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ADRA1D P25100 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
KIF11 P52732 1/20 0.39
EPHX2 P34913 4/20 0.39
NR1H4 Q96RI1 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348623 0.78 TSHR (0.52) TSHRLMNATYRKCNH2TP53
SCHEMBL7456580 0.78 KCNH2 (0.59) TSHRLMNATYRKCNH2TP53
SCHEMBL424728 0.76 TSHR (0.73) TSHRLMNATYRBCHEACHE
SCHEMBL11961978 0.76 ESR1 (0.32) TSHR
SCHEMBL338386 0.76 BCHE (0.52) TSHRLMNATYRKCNH2TP53
SCHEMBL715835 0.75 TSHR (0.44) TSHRLMNATYRKCNH2TP53
SCHEMBL3670168 0.74 TSHR (0.48) TSHRLMNATYRKCNH2TP53
SCHEMBL19454941 0.74 ESR1 (0.58) TSHRLMNATYRKCNH2TP53
SCHEMBL1351590 0.74 TSHR (0.48) TSHRLMNATYRKCNH2TP53
SCHEMBL121893 0.74 TSHR (0.48) TSHRLMNATYRKCNH2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2011-06-23 US disclosed
WO-2008134474-A2 COMPOSITIONS AND METHODS INCLUDING CELL DEATH INDUCERS AND PROCASPASE ACTIVATION THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME TRPV1, TRPA1, TRPV2 TSHR 2249/4885LMNA 4181/4885TYR 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.